Loading clinical trials...

In Vitro Effects of Procyanidine on Semen Parameter and DFI | Clinical Trials | Clareo Health

COMPLETEDNA

In Vitro Effects of Procyanidine on Semen Parameter and DFI

In Vitro Effects of Procyanidine on Semen Parameters and DNA Fragmentation Index: a Prospective, Double-blind Trial

NCT03414164•Aristotle University Of Thessaloniki

Summary

Proanthocyanidins are a class of polyphenols found in a variety of plants that have antioxidant activity in vitro, which is stronger than vitamin C or vitamin E. Several studies have been performed evaluating the administration of antioxidant therapy in the form of oral antioxidant supplementation or in vitro addition of antioxidant to culture media during assisted reproductive techniques (ART). However, the impact of in vitro addition of proanthocyanidins to semen has not been studied yet. The research question evaluated in the current study was whether semen samples of infertile men supplemented or not with procyanidine immediately after their production, differ in semen parameters, sperm DFI.

Eligibility

Age

18 - 50 years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•Infertility defined as:
•* At least twelve (12) months of non-achieving pregnancy despite unprotected sexual intercourse or six (6) months, if the female is \> 35 years of age AND
•* At least two (2) semen analyses with at least one abnormal parameter (sperm concentration, motility and morphology), according to WHO 2010 criteria.
•Not on any type of infertility treatment for the last three (3) months
•Sperm concentration \> 8 x 106/ml and semen volume at least 2.5 ml for technical reasons.
•Normal hormonal profile (TSH, FSH, LH, total testosterone, prolactin)
•Seminal white blood cells \< 1 x 106/ml
•No abnormalities in scrotal ultrasound

Exclusion Criteria

•Underlying genetic cause of infertility
•History of undescended testis (cryptorchidism)
•History of orchidectomy
•History of testicular cancer
•History of severe cardiac, hepatic or renal disease.
•History of endocrine disease (primary or secondary hypogonadism, hyperprolactinemia, thyroid disease, pituitary or adrenal disease)
•History of epididymo-orchitis, prostatitis, genital trauma, testicular torsion, inguinal or genital surgery
•History of systemic disease or treatment during the last three (3) months
•Positive sperm culture for Chlamydia or Ureaplasma urealyticum
•Female infertility factors
+2 more criteria

Locations (1)

Stratis Kolibianakis

Thessaloniki, Greece

Key Dates

Start Date

April 29, 2017

Primary Completion Date

November 30, 2017

Completion Date

December 31, 2017

Last Updated

January 29, 2018

Enrollment

ACTUAL participants

Conditions

Spermatogenesis and Semen DisordersDNA Double Strand Break

Interventions

procyanidine

DIETARY_SUPPLEMENT

Prospective Study on Power Prenatal Vitamins for Males on YO Score At-home Sperm Test Results

NCT05951075

Spermatogenesis and Semen DisordersInfertility, Male

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 29, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions